Hemophilia Treatment Market Size By Disease (Hemophilia A {Severe, Moderate, Mild}, Hemophilia B {Severe, Moderate, Mild}), By Product (Recombinant Factor Concentrates {Factor VIII, Factor IX}, Plasma-derived Factor Concentrates {Factor VIII, Factor IX},

Hemophilia Treatment Market Size By Disease (Hemophilia A {Severe, Moderate, Mild}, Hemophilia B {Severe, Moderate, Mild}), By Product (Recombinant Factor Concentrates {Factor VIII, Factor IX}, Plasma-derived Factor Concentrates {Factor VIII, Factor IX}, Extended Half-life Products {Factor VIII, Factor IX}), By Patient (Pediatric {0 to 4, 5 to 13, 14 to18}, Adult {19 to 44, 45+}), By Treatment (Prophylaxis, On Demand), By Therapy (Factor Replacement Therapy, Non-factor Replacement Therapy), By Drug Class (Vasopressin, Coagulation Factors), By Route of Administration (Injectable, Nasal Spray), By End-use (Hospitals, Clinics, Hemophilia Treatment Centers), Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2028

The global hemophilia treatment market is expected to grow at a significant rate through 2028 owing to growing prevalence of advanced hemophilia treatment across the world.

In the United States, almost 70% of the patients with hemophilia receive multidisciplinary, comprehensive care through a network of federally sponsored hemophilia treatment clinics. People who received care in hemophilia treatment facilities had a 40% lower mortality rate and a 40% lower rate of hospitalization for hemophilia-related bleeding problems than those who did not, which has positively impacted product adoption in recent years.

Overall, the hemophilia treatment market has been segmented in terms of disease, product, patient, treatment, therapy, drug class, route of administration, end-use, and region. Based on disease, the market has been classified into hemophilia A and hemophilia B. In 2021, the hemophilia B segment held a considerable share in the market and is expected to record the fastest growth at a CAGR of about 3.5% through the assessment timeline fueled by mounting incidences of hemophilia B as well as increasing need for having advanced treatments across the world.

With respect to the product, the hemophilia treatment market has been categorized into plasma-derived factor concentrates, extended half-life products, recombinant factor concentrates, and others. The recombinant factor concentrates segment was valued at around USD 7,000 million in 2021 and is projected to witness substantial growth through 2028 on account of several benefits that are offered by recombinant factor concentrates in hemophilia treatment.

With respect to patient, the market has been divided into pediatric and adult. Due to the rising cases of hemophilia seen among adults, the adult segment is anticipated to grow at a lucrative rate of over 4.9% through the review period to accumulate roughly USD 9,947 million in revenue by the end of 2028.

With regards to treatment, the hemophilia treatment market has been divided into on demand and prophylaxis. In 2021, the prophylaxis segment was worth more than USD 7,998 million and is expected to register steady growth at more than 5.0% CAGR between 2022 and 2028. This growth is attributable to improved clinical results with the use of innovative treatment solutions, particularly in younger patients.

On the basis of therapy, the hemophilia treatment market has been bifurcated into factor replacement therapy and non-factor replacement therapy. The non-factor replacement therapy segment surpassed a valuation of USD 1,648 million in 2021 and is expected to develop rapidly through 2028 due to several advantages of the therapy, such as reduced treatment load, increased ability to provide prophylaxis treatment to patients, and so on.

By drug class, the market has been divided into vasopressin and coagulation factors. The vasopressin segment was valued at about USD 573 million in 2021 and is poised to see notable growth impetus over 2022-2028 on account of improved survival rates in critical patients, clinical efficacy and safety, and other factors.

Based on the route of administration, the hemophilia treatment market has been categorized into injectable and nasal spray. By the end of 2028, the injectable segment is expected to grow at a CAGR of approximately 4.9% to garner a valuation of around USD 14,655 million. The fast-acting and efficient mechanism of drug delivery given by injectables is foreseen to support segmental growth.

With respect to end-use, the hemophilia market has been classified into hospitals, clinics, hemophilia treatment centers, and others. The hospitals segment was valued at more than USD 3,382 million in 2021 and is the fastest expanding segment with a growth rate of about 5.2% through the review timeline driven by surging availability of board-certified competent hematologists and the necessity of delivering quality treatment plans, among other factors.

On the regional front, the Latin America hemophilia treatment market was estimated to be valued at over USD 577 million in 2021 and is speculated to witness sturdy progress at a CAGR of nearly 5.4% through 2028. Rising awareness regarding hemophilia treatment across LATAM is slated to drive regional market growth over the forecast period.